[{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Bloom Burton Securities Inc"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"AAK1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Satellos Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the Offering to advance clinical development of SAT-3247. It is being evaluated for the treatment of Duchenne Muscular Dystrophy.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 17, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Bloom Burton Securities Inc

                          Deal Size : $40.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 01, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 18, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 08, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 11, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 02, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the notch pathway. It is being developed for the treatment of duchenne muscular dystrophy.

                          Product Name : SAT-3247

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 28, 2024

                          Lead Product(s) : SAT-3247

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank